Panaxia Labs Israel Ltd represents a strong commitment to innovation, quality, and patient care. The company values encompass cutting-edge research and development, ensuring effective and safe pharmaceutical solutions. With a focus on technological advancement, Panaxia Labs Israel Ltd strives to enhance the therapeutic potential of medical cannabis-based products. The company's corporate philosophy centers around transparency, integrity, and professionalism, placing great importance on adhering to strict regulatory standards. Panaxia Labs Israel Ltd aims to provide reliable and accessible medicinal cannabis options that prioritize patient well-being and improve their quality of life.

Panaxia Labs Israel Ltd is primarily present in Israel.

Panaxia Labs Israel Ltd has achieved several significant milestones. The company has established itself as a leading provider of pharmaceutical cannabis products in Israel and internationally. It has developed innovative pharmaceutical-grade medical cannabis products, including oils, capsules, and inhalers. Panaxia has also pioneered advanced extraction and purification processes, ensuring the highest quality standards for its products. The company has strong collaborations and partnerships in the medical cannabis industry and has been expanding its global reach through strategic alliances. Panaxia Labs Israel Ltd continues to make groundbreaking advancements in the field of medical cannabis research, production, and distribution.

Panaxia Labs Israel Ltd. is a renowned pharmaceutical company based in Israel. With a rich history spanning several years, Panaxia Labs has established itself as a leader in the field of medical cannabis products. The company specializes in developing, manufacturing, and distributing innovative and high-quality pharmaceutical cannabis products. Panaxia Labs is committed to delivering optimal therapeutic solutions to patients, backed by rigorous research, development, and quality control processes. Through strategic collaborations and partnerships, the company strives to advance medical cannabis treatments and cater to a diverse range of patient needs. Panaxia Labs Israel Ltd. continues to drive innovation and growth in the global cannabis industry.

Some of the main competitors of Panaxia Labs Israel Ltd in the market include Tikkun Olam, BOL Pharma, and Tikun Pharmaceuticals.

Panaxia Labs Israel Ltd is primarily active in the pharmaceutical and medical industries.

The business model of Panaxia Labs Israel Ltd revolves around pharmaceutical solutions and cannabis-based products. As a leading Israeli company in the field, Panaxia Labs specializes in the development, production, and distribution of advanced medical cannabis treatment methods. They constantly innovate and provide comprehensive pharmaceutical solutions, which integrate the benefits of cannabis for patients in need. Panaxia Labs Israel Ltd focuses on the research and development of new drugs, medical devices, and treatment protocols, ensuring the highest quality standards are met to serve the healthcare industry and improve patients' well-being.

KGV-d ei saa praegu Barak Investment House jaoks arvutada.

KUV-d ei ole võimalik hetkel Barak Investment House jaoks arvutada.

AlleAktien kvaliteediskoor ettevõttele Barak Investment House on 1/10.

Praegu ei saa Barak Investment House käivet arvutada.

Praegu ei ole võimalik kasumit Barak Investment House jaoks arvutada.

The company Panaxia Labs Israel Ltd is a leading company in the development, manufacturing, and marketing of pharmaceuticals, medical devices, and accessory products. The business model is based on innovative technology and continuous exploration of new methods and solutions to meet the needs of patients, healthcare providers, and the pharmaceutical industry. The company's divisions span a variety of areas, including pain treatment, oncology, neurology, psychiatry, and infectious diseases. The company has also specialized in the production of products for veterinary medicine purposes. A key product from Panaxia Labs is the pain pill Panaxia, which contains THC and CBD and provides pain relief without the potential side effects of opioids. The pill is already available in Israel and is soon to be introduced to other countries. Panaxia Labs also offers a range of medical devices and accessory products, such as automatic inhalers tailored to the needs of asthmatics, as well as indicators for monitoring blood sugar levels in diabetics. The company has a state-of-the-art production facility in Israel that meets the highest industry standards and operates under ISO 13485 and GMP certification. Panaxia Labs has close relationships with leading academic institutions, research organizations, and government agencies. This allows the company to stay informed about new developments and market trends and constantly improve its products. Panaxia Labs has also entered partnerships with companies in the pharmaceutical industry and the technology sector to jointly develop innovative products. For example, the company has entered into an agreement with Rafa Cannabis to integrate Rafa's THC and CBD products into Panaxia products. To further drive its business and market its products globally, Panaxia Labs recently entered into a partnership with PharmaCielo Ltd., a leading company in the legal cultivation and production of medical cannabis in Colombia. Panaxia Labs will distribute PharmaCielo's products in Israel, while PharmaCielo will handle the marketing of Panaxia products in Colombia. Overall, Panaxia Labs' business model offers a promising future for the company and the patients it serves. With innovative products, world-class production, and strong partnerships, Panaxia Labs will take a leading role in the pharmaceutical industry and improve people's lives around the world.

Barak Investment House maksab dividendi 0 ILS, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Barak Investment House jaoks arvutada või ettevõte ei maksa dividende välja.

Barak Investment House ISIN on IL0011043630.

Barak Investment House tähis on BARI.TA.

Viimase 12 kuu jooksul maksis Barak Investment House dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Barak Investment House tõenäoliselt dividendi summas 0 ILS.

Barak Investment House praegune dividenditootlus on .

Barak Investment House maksab kvartaalset dividendi. See makstakse välja kuudel .

Barak Investment House maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 ILS. See vastab dividenditootlusele 0 %.

Barak Investment House on liigitatud sektorisse 'Tervis'.

Viimase Barak Investment House dividendide saamiseks 15.6.2012 suuruses 1,074 ILS pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 3.6.2012.

Viimane dividendimakse toimus 15.6.2012.

Aastal 2023 maksis Barak Investment House 0 ILS dividende.

Barak Investment House dividendid makstakse välja ILS.